MedTrace Logo

Preventive Effectiveness, Safety and Immunogenicity of a Allantoic Split Inactivated Seasonal Influenza Vaccine

NCT03572491 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2000

Last updated 2018-06-28

No results posted yet for this study

Summary

The study is Multicenter, phase 3, Open-Label trial that explored the preventive effectiveness, safety and immunogenicity of single dose a allantoic split inactivated seasonal influenza vaccine in healthy adults.

Conditions

  • Human Influenza

Interventions

BIOLOGICAL

influenza vaccine

Allantoic split inactivated seasonal influenza vaccine

Sponsors & Collaborators

  • Asfendiyarov Kazakh National Medical University

    collaborator OTHER

  • Research Institute of Influenza, Russia

    collaborator OTHER

  • Research Institute for Biological Safety Problems

    lead OTHER_GOV

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-09-18
Primary Completion
2018-05-21
Completion
2018-05-21

Countries

  • Kazakhstan

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03572491 on ClinicalTrials.gov